Pharmaceutical services firm Hvivo, formerly Open Orphan, will pay a dividend to shareholders after a “record financial and operational performance” last year. The Dublin and London-listed organisation is set to

Bruno Speder, VP of regulatory affairs & consultancy services, hVIVO, discusses how Human Challenge Trials (HCT) can be used in the framework of expedited review programs as part of drug and

The Challenge Malaria is a serious and life-threatening, mosquito borne disease prevalent across much of tropical and sub-tropical Asia, South America and Sub-Saharan Africa. Due to increasing resistance to current

Hvivo, formerly known as Open Orphan, has reported a 30 per cent jump in revenue to £50.6 million (€57.2 million) for last year. The Dublin and London-listed pharmaceutical company said

Everybody knows what the common cold and influenza are, but we’d guess not many have heard of RSV (Respiratory Syncytial Virus). So, what it is? Well, it is a very

Chief Scientific Officer, Andrew Catchpole discusses hVIVO’s attendance at the World Vaccine Congress in Washington. hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and